Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

Novavax (NASDAQ:NVAX) executives told investors the company made “significant progress” in 2025 executing a strategy centered ...

(Reuters) -Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Shares of Novavax Inc. NVAX slid 1.51% to $10.08 Monday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite Index COMP rising 1.22% to 22,374.18 ...

Vaccine biotechnology company Novavax (NASDAQ:NVAX) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 66.6% year on year to $147.1 million. Its GAAP profit of $0.11 ...

The MarketWatch News Department was not involved in the creation of this content. -- Non-exclusive license allows for development by Pfizer to utilize Matrix-M(R) for up to two disease areas with its ...

Novavax reported fourth-quarter earnings of 11 cents, a shift from a loss of 51 cents a year ago. evenue for the fourth quarter was $147 million, a 67% year-over-year increase. Novavax on Thursday ...